Patients of CCA (mostly iCCA) with mutations in BAP1, a tumor suppressor gene involved in DNA double-strand break repair, are reported to have an aggressive disease and poor response to standard therapies [75]. This evidence concerns the gene BAP1 and cholangiocarcinoma.